Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 12/2012

01-12-2012 | Case Report

Ortner’s syndrome as a presenting feature of giant cell arteritis

Author: Amr Edrees

Published in: Rheumatology International | Issue 12/2012

Login to get access

Abstract

Hoarseness due to left recurrent laryngeal nerve paralysis (LRLN) caused by identifiable cardiovascular disease is described as Ortner’s syndrome or cardiovocal syndrome. This was first reported by Ortner in 1897 to describe left recurrent laryngeal nerve palsy secondary to mitral stenosis. This case report describe a patient with giant cell arteritis with initial presentation of Ortner’s syndrome.
Literature
1.
Ortner NI (1897) Recurrenslähmung bei Mitralstenose. Wien Klin Wochenschr 10:753–755
2.
Escribano JF et al (2006) Ortner’s syndrome and endoluminal treatment of a thoracic aortic aneurysm: a case report. Vasc Endovascular Surg 40(1):75–78PubMedCrossRef
3.
Gray H, Bannister LH, Berry MM, Williams A (1995) Gray's anatomy: the anatomical basis of medicine & surgery, 38th edn. Churchill Livingstone, Philadelphia, pp 1251–1253
4.
Hunder GG, Block DA, Michel BA et al (1990) The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Artheritis Rheum 33:1122–1128CrossRef
5.
McMillan G (1950) Diffuse granulomatous aortitis with giant cells associated with partial rupture and dissection of the aorta. Arch Pathol 49:63–69
6.
Nuenninghoff DM, Hunder GG, Christianson TJH et al (2003) Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis a population based study over 50 years. Arthritis Rheum 48:3522–3531PubMedCrossRef
7.
Bongartz T, Matteson EL (2006) Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 18:10–17PubMedCrossRef
Metadata
Title
Ortner’s syndrome as a presenting feature of giant cell arteritis
Author
Amr Edrees
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1533-z

Other articles of this Issue 12/2012

Rheumatology International 12/2012 Go to the issue

Original Article

Investigation of the change in CD4+ T cell subset in children with Henoch–Schonlein purpura

Original Article

Reevaluation of predictive value of ACL and anti-β2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world

Original Article

Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea

Short Communication

Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab

Original Article

Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center

Original Article

25-Hydroxyvitamin D levels and juvenile idiopathic arthritis: Is there an association with disease activity?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits